Shares of Arvinas Holding Company LLC (ARVN) are soaring 5.08% in Monday's intraday trading session, following positive analyst actions from Stephens & Co. The biotechnology company's stock is gaining momentum after Stephens raised its price target and reaffirmed its bullish stance on the company.

Stephens & Co. has increased its target price for Arvinas from $14 to $15, signaling growing confidence in the company's potential. Additionally, the firm has maintained its Overweight rating on ARVN stock, suggesting that they believe the stock will outperform the sector in the coming period.

This upbeat assessment from Stephens appears to be driving investor enthusiasm, pushing Arvinas' stock higher. The raised price target and maintained Overweight rating indicate that analysts see further upside potential in the company, despite the challenging market conditions facing many biotechnology firms. Investors will likely be watching closely for any further developments or announcements from Arvinas that could sustain this positive momentum.